Disclosures Konstantin Articus, Monika Baier and Ferenc Tracik are full-time employees of Novartis Pharma GmbH, the sponsor of this study. Novartis Pharma GmbH developed and manufactures the rivastigmine patch. Ulrich W. Preuß has financial interests/arrangements or affiliations with one or more organisations that could be perceived as a conflict of interest in the context of the subject of this manuscript. He has received research support, consultancy, or lecture fees from Pfizer, Astra-Zeneca, Eli-Lilly, Janssen-Cilag, and Novartis in the past 3 years. Frank Kühn and Alexander Kurz have no conflicts of interest to declare.Clinical Trails for Identifier:NCT00561392
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease
Version of Record online: 6 JUN 2011
© 2011 Blackwell Publishing Ltd
International Journal of Clinical Practice
Volume 65, Issue 7, pages 790–796, July 2011
How to Cite
Articus, K., Baier, M., Tracik, F., Kühn, F., Preuß, U. W. and Kurz, A. (2011), A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease. International Journal of Clinical Practice, 65: 790–796. doi: 10.1111/j.1742-1241.2011.02713.x
- Issue online: 16 JUN 2011
- Version of Record online: 6 JUN 2011
- Paper received December 2010, accepted March 2011
- 9A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65., , .
- 15Dose-response effect of rivastigmine in the treatment of Alzheimer’s disease. Int J Geriatr Psychopharmacol 2000; 2: 68–72., , .
- 17Drug persistency patterns for patients treated with rivastimgine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231–39., , et al.